Majid Rahimifar, MD
Neurosurgery · Bakersfield, CANPI 1528018785
Payments from drug & device makers
What this record shows
This record is dominated by other: $28,751 of the $29,552 with a category attached, or 97.3%. Olympus America Inc. accounts for 97.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $28,781 and has fallen 99.9% since, to $21 in 2025.
Across 40 payments — averaging $738.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$29K
- Livanova USA, Inc.$110
- Eisai Inc.$95
- EMD Serono, Inc.$83
- Acorda Therapeutics, Inc$80
- Cerapedics Inc.$73
- plus $360 from 13 others
What the payments were for
- Speaking & faculty fees$570%
- Food & beverage$7443%
- Other$28,75197%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 1 | $28,751 |
| Livanova USA, Inc. | 5 | $110 |
| Eisai Inc. | 5 | $95 |
| EMD Serono, Inc. | 4 | $83 |
| Acorda Therapeutics, Inc | 4 | $80 |
| Cerapedics Inc. | 1 | $73 |
| Merz Pharmaceuticals, LLC | 2 | $58 |
| Abbott | 2 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Stryker | 3 | $36 |
| Axonics, Inc. | 2 | $29 |
| Titan Spine, LLC | 1 | $28 |
| AbbVie(2 entities) | 2 | $25 |
| Merck | 1 | $21 |
| Integra Lifesciences Corporation | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Si-bone, Inc. | 1 | $17 |
| Medtronic | 1 | $12 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Olympus$28,751
How this compares
$29,552 in reported general payments places this provider in the 85th percentile of 25 neurosurgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 236 | $2,450 |
| Gabapentin | 232 | $1,598 |
| Nortriptyline Hcl | 59 | $419 |
| Cyclobenzaprine Hcl | 87 | $338 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 53 | $292 |
| Levetiracetam | 20 | $266 |
| Cephalexin | 18 | $227 |
| Meloxicam | 15 | $67 |
| Ibuprofen | 14 | $38 |
| Tramadol Hcl | 20 | $34 |
Paid to pharmacies, not to this prescriber.
Other neurosurgery in Bakersfield
- Frank Yoola Jolla$605K
- Doris WangSan Francisco$110K
- Line JacquesSan Francisco$32K
- James TateRedding$15K
- Kenneth BlumenfeldSan Jose$3K
- Anthony DigiorgioGreenbrae$2K
- Stephen MendenhallVacaville$2K
- Ezequiel GoldschmidtNewport Beach$1K
- Moris SenegorStockton$1K
- Azim LaiwallaLos Angeles$975
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.